Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab + Belumosudil in Belumosudil-refractory cGVHD
NCT07484113Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- May 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of sarilumab in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Stanford University. Primary endpoint: Incidence of treatment-emergent adverse events at 6 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07484113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484113.